STELLIUM 1: First-in-man follow-up evaluation of bioabsorbable polymer-coated paclitaxel-eluting stent

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2089-2096

  Kozuki, Amane ^a   Shite, Junya ^a   Shinke, Toshiro ^a   Miyoshi, Naoki ^a   Sawada, Takahiro ^a   Hellig, Farrel ^b   Abelson, Mark ^c   Brown, Basil ^d   Khan, Sajidah ^e   Mpe, Martin ^f   Ntsekhe, Mpiko ^g   Conway, Damian ^h   Hirata, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sunward Park Hospital   (South Africa)

^c Vergelegen Hospital   (South Africa)

^d Provincial Hospital   (South Africa)

^e Inkosi Albert Luthuli Hospital   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Department of Neurology   (South Africa)

^h DISA Vascular Ltd   (South Africa)

Author keywords

Bioabsorbable polymer; Neointima; Optical coherence tomography; Paclitaxel eluting stents

Indexed keywords

PACLITAXEL; POLYGLACTIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOINTIMA; PACLITAXEL; POLYMERS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; TREATMENT OUTCOME;

EID: 77958075954     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0859     Document Type: Article

References (34)

1. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
2. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
5. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
8. Abal M, Andreu JM, Barasoain I. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3: 193-203.
9. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-2295.
10. Jabara R, Chronos N, Tondato F, Conway D, Molema W, Park K, et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel- eluting stent in pig coronary arteries. J Invasive Cardiol 2006; 18: 383-390.
11. Jabara R, Chronos N, Conway D, Molema W, Robinson K. Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating. J Am Coll Cardiol Cardiovasc Interv 2008; 1: 81-87.
12. Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. J Am Coll Cardiol 2002; 39: 604-609.
13. Bouma BE, Tearney GJ, Yabushita H, Shishkov M, Kauffman CR, DeJoseph Gauthier D, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003; 89: 317-320.
14. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, et al. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111: 1551-1555.
15. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006; 97: 1713-1717.
16. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967.
17. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, et al. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. J Am Coll Cardiol Cardiovasc Interv 2008; 1: 168-173.
18. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6- month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
19. Yamaguchi T, Terashima M, Akasaka T, Hayashi T, Mizuno K, Muramatsu T, et al. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol 2008; 101: 562-567.
20. Kataiwa H, Tanaka A, Kitabata H, Imanishi T, Akasaka T. Safety and usefulness of non-occlusion image acquisition technique for optical coherence tomography. Circ J 2008; 72: 1536-1537.
21. Sawada T, Shite J, Negi N, Shinke T, Tanino Y, Ogasawara D, et al. Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography. Circ J 2009; 73: 1841-1847.
22. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
23. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
24. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
25. Dani S, Kukreja N, Parikh P, Joshi H, Prajapati J, Jain S, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention 2008; 4: 59-63.
26. Kaluza GL, Kiesz S, Gil R. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheter Cardiovasc Intervent 2008; 71: 51-57.
27. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
28. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
29. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
30. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
31. Miyoshi N, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Comparison of paclitaxel-eluting stents with sirolimus-eluting stents implanted in a single coronary artery in one procedure by optical coherence tomography: 6-month follow-up. Circ J 2010; 74: 903-908.
32. Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008; 94: 566-570.
33. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, et al. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. J Am Coll Cardiol Cardiovasc Interv 2009; 2: 459-466.
34. Teramoto T, Ikeno F, Otake H, Lyons JK, van Beusekom HMM, Fearon WF, et al. Intriguing peri-strut low-intensity area detected by optical coherence tomography after coronary stent deployment. Circ J 2010; 74: 1257-1259.